에 대한 최신 뉴스 Guardant Health (NASDAQ:GH) 주식

GUARDANT HEALTH INC

Guardant Health

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Kyiv,,Ukraine,-,February,25,,2021:,In,This,Photo,Illustration

Equities

Markets

ETFs

ARKK

ARKW

HOOD

PLTR

RBLX

목요일(1일) 캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 로빈후드 마켓츠(NASDAQ:HOOD), AMD(NASDAQ:AMD), 그리고 팔란티어 테크놀로지스(NASDAQ:PLTR)와 관련된 중요한 거래를 했다.

캐시 우드, 암호화폐 수익 감소에도 로빈후드에 980만 달러 투자, 실적 발표 전 팔란티어 매도 지속

Logo,Pfizer,Inc.,Is,An,American,Multinational,Pharmacological,And,Biotechnology

Earnings

News

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

화이자(NYSE:PFE)는 4월 29일 화요일 개장 전에 1분기 실적을 발표할 예정다.애널리스트들은 뉴욕에 본사를 둔 화이자가 주당 68센트의 분기 수익을 발표할 것으로 예상하고 있다. 이는 전년 동기 82센트에 비해 감소한 수치다. 또한 140억 9천만 달러의 분기 매출을 발표할 것으로 예상되며, 이는 전년 동기 148억 8천만 달러에 비해 감소한 수치다. 

화이자 1분기 실적 발표 임박···월가 최고 애널리스트들의 최근 의견 변동은?

Chase Freedom Unlimited®

Mid Cap

Movers

HIMX

OKLO

RGTI

SGHC

이들 8개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 오클로(NYSE:OKLO)의 주식은 금요일 회사가 R파워와 데이터 센터를 위한 청정 에너지 제공에 대한 MoU를 체결했다고 발표한 후 72.60% 상승했다.

오클로 및 리제티 컴퓨팅 등 지난주 최대 상승한 8개의 중형주 (1월 20일-1월 24일)

Guardant Health Inc

Gresham Technologies PLC

Grand Havana Inc

Glass House Brands Inc Warrants (15/01/2026)

Glass House Brands Inc

Graham Holdings Co

Galaxy Heroes Coin

GOLD HART COPPER CORP by GOLD HART COPPER CORP.

Collaborative Investment Series Trust Goose Hollow Hedged Equity ETF

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Group Ltd

GUANHUA CORPORATION by GuanHua Corporation

GuanHua Corp

Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

Greystone Housing Impact Investors LP

Gamehost Inc

GREEN AND HILL INDUS INC by Green and Hill Industries, Inc.

Green and Hill Industries Inc

Gores Holdings IX Inc Ordinary Shares - Class A

Gores Holdings IX Inc

Gores Holdings IX Inc Units (1 Ord Class A & 1/3 War)

Gores Holdings IX Inc Warrants (31/01/2027)

Greenhill & Co Inc Com

Guild Holdings Company Class A Common Stock

Guild Holdings Co

Graham Corp

Accredited Solutions Inc

Collaborative Investment Series Trust Goose Hollow Multi-Strategy Income ETF

GHO - United States Dollar

Ghost

GOLD HUNTER RES INC by GOLD HUNTER RES INC

Gold Hunter Resources Inc

GOLDEN HORSE MINERALS LTD by GOLDEN HORSE MINERALS LTD

Golden Horse Minerals Ltd

GH Research PLC

GREENHEART GOLD INC by Greenheart Gold Inc.

Guardion Health Sciences Inc

GHST World Inc

Aavegotchi - United States Dollar

Goose Hollow Tactical Allocation ETF

G-H-3 INTERNATIONAL INC by G-H-3 International, Inc.

G-H-3 International Inc

GoldHaven Resources Corp Ordinary Shares

GOLDHAVEN RESOURCES CORP by GoldHaven Resources Corp

GoldHaven Resources Corp

GamerCoin

PGIM Global High Yield Fund, Inc

Goldman Sachs Access High Yield Corporate Bond ETF

iShares US & Intl High Yield Corp Bond ETF

GOLD HYDROGEN LIMITED by Gold Hydrogen Limited

Gold Hydrogen Ltd

<a href="https://www.bloomberg.com/news/articles/2025-06-03/china-s-nio-to-reduce-r-d-costs-to-hit-break-even-goal?srnd=homepage-americas&amp;embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-03/china-s-nio-to-reduce-r-d-costs-to-hit-break-even-goal?srnd=homepage-americas&amp;embedded-checkout=true</a>

General

'Chinese EV Maker Nio to Reduce R&D Costs to Hit Break-Even Goal'- Bloomberg

Telsey Advisory Group analyst Dana Telsey maintains Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) with a Market Perform and maintains $62 price target.

Telsey Advisory Group Maintains Market Perform on Signet Jewelers, Maintains $62 Price Target

Student loan debt in the United States has reached unprecedented levels, with borrowers collectively owing more than $1.77 trillion as of 2025, according to the Education Data Initiative.&nbsp;
As tuition costs continue to rise, many graduates struggle to manage monthly payments which can lead to challenges including delinquency, default and<a href="https://www.benzinga.com/personal-finance/management/25/06/45739976/trump-administration-pauses-social-security-garnishments-over-defaulted-student-loans-department-will-begin-proactive-outreach-to-recipients"> long-term financial insecurity.&nbsp;</a>
One TikTok-er has a "solution."&nbsp;
Read Next: <a href="https://www.benzinga.com/news/space/25/06/45724938/space-stocks-weekly-countdown-rocketlab-gets-analyst-love-while-virgin-galactic-slides-into-june?utm_source=articleShare">Space Stocks Weekly Countdown: RocketLab Gets Analyst Love While Virgin Galactic Slides Into June</a>
The Details: TikTok user @thenormajeane5 recently went viral with <a href="https://www.tiktok.com/@thenormajeane5/video/7509221877844446510?lang=en">a post</a> detailing his unconventional strategy: staying in school indefinitely to keep student loans in deferment and avoid repayment.&nbsp;
<figure class="wp-block-embed is-type-video is-provider-tiktok wp-block-embed-tiktok"> 
<div class="wp-block-embed__wrapper">
<blockquote class="tiktok-embed" cite="https://www.tiktok.com/@thenormajeane5/video/7509221877844446510" data-video-id="7509221877844446510" data-embed-from="oembed" style="max-width:605px; min-width:325px;"> <section> <a target="_blank" title="@thenormajeane5" href="https://www.tiktok.com/@thenormajeane5?refer=embed">@thenormajeane5</a>
For legal purporses this is SATIRE: I'm never going to pay back those student loans. &#8211; don't get me wrong I know it's inevitable and I hope to be in a better place in the future I guess. 
 <a target="_blank" title="♬ Don't Forget About Us - KAYTRANADA Remix - Mariah Carey &#038; KAYTRANADA" href="https://www.tiktok.com/music/Don't-Forget-About-Us-KAYTRANADA-Remix-7489248146356586512?refer=embed">♬ Don&#8217;t Forget About Us &#8211; KAYTRANADA Remix &#8211; Mariah Carey &#038; KAYTRANADA</a> </section> </blockquote>
<script async src="https://www.tiktok.com/embed.js"></script></div>
</figure>
Thenormajeane5, who is currently working toward a doctoral degree, explained that after graduating in about two and a half years, he plans to keep pursuing associate degrees for the rest of his life in order to remain a lifelong student and postpone repayment indefinitely.&nbsp;
The creative approach resonated with thousands online, racking up nearly 500,000 likes and more than 11,000&nbsp; comments.&nbsp;
Many viewers shared similar stories. One commenter said their professor had over $800,000 in student loans and was still enrolled, joking that he'd never pay it back. Another mentioned their grandmother, who kept enrolling in new degrees and was about to graduate with her master's degree.&nbsp;
Others described using employer tuition reimbursement programs to keep taking classes, or simply repeating the deferment strategy for years.&nbsp;
Read Next: <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45727360/amazon-analyst-sees-robotics-unlocking-billions-in-savings?utm_source=articleShare">Amazon Analyst Sees Robotics Unlocking Billions In Savings</a>
Other Options: Student loan borrowers have other, perhaps more financially responsible options, including income-driven repayment plans and student loan refinancing.&nbsp;
Borrowers struggling to repay federal student loans can apply for an <a href="https://studentaid.gov/manage-loans/repayment/plans/income-driven#:~:text=An%20income%2Ddriven,0%20per%20month.">income-driven repayment</a> plan which bases monthly student loan payment amounts on income and family size. For some people, payments on an IDR plan can be as low as $0 per month.
Borrowers with private student loans have other options like refinancing in order to achieve lower monthly payments. SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) specializes in student loan refinancing and Citizens Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>) offers student loan refinancing through Citizens Bank.&nbsp;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/management/25/05/45675714/can-michael-burrys-nvidia-short-survive-the-stocks-stunning-comeback?utm_source=articleShare">Can Michael Burry&#8217;s Nvidia Short Survive The Stock&#8217;s Stunning Comeback?</a></li>
</ul>
Image: Shutterstock

Social Media

Personal Finance

SOFI

The Viral Student Loan Solution People Can't Stop Talking About

Stifel analyst Matthew Smith maintains The Campbell's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) with a Hold and lowers the price target from $40 to $38.

Stifel Maintains Hold on The Campbell's, Lowers Price Target to $38

Telsey Advisory Group analyst Cristina Fernandez maintains Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Outperform and maintains $60 price target.

Telsey Advisory Group Maintains Outperform on Academy Sports, Maintains $60 Price Target

Stifel analyst Selman Akyol maintains Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) with a Hold and raises the price target from $27 to $28.

Stifel Maintains Hold on Kinder Morgan, Raises Price Target to $28

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) may be setting up for a massive rally if its long-term logarithmic growth channel holds, according <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">to traders&#8217; analysis.</a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1949</td>
<td>$29.2 billion</td>
<td>+2.7%&nbsp;</td>
<td>-14.9%&nbsp;</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001315</td>
<td>$7.8 billion</td>
<td>+2.9%&nbsp;</td>
<td>-9.5%&nbsp;</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>&nbsp;$0.00001260</td>
<td>$5.3 billion</td>
<td>+8.9%&nbsp;</td>
<td>-10.2%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: On June 3, crypto analyst Kevin highlighted a key support zone between $0.1839 and $0.1901 as a launchpad for the next leg higher.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Come on <a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> show us what your made of &#x1f91d; <a href="https://t.co/5omq3H4ppQ">https://t.co/5omq3H4ppQ</a> <a href="https://t.co/ndgJ7Ms1vc">pic.twitter.com/ndgJ7Ms1vc</a>
&mdash; Kevin (@Kev_Capital_TA) <a href="https://twitter.com/Kev_Capital_TA/status/1929711717069758638?ref_src=twsrc%5Etfw">June 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto Tony <a href="https://x.com/CryptoTony__/status/1929863383601332651">remains</a> long from $0.148, expecting a breakout above $0.248 to confirm the next move. 
Trader Tardigrade pointed to Dogecoin's 3-day RSI hovering around 50, a level that has historically preceded major rallies, with upside potential toward $1.
Meanwhile, Bitcoinsensus <a href="https://x.com/Bitcoinsensus/status/1929469386957713620">identified</a> that DOGE has been respecting a logarithmic channel since 2014. 
Past performances include: a 10x from 2014 to 2017 and a 37x from 2017 to 2021. 
This could lead to a possible 21x from 2021 to a projected 2025 peak.
If this pattern plays out, DOGE could reach up to $16, an extraordinary gain backed by a decade of price action rather than just short-term hype.
Statistics: On May 31, Whale Alert <a href="https://x.com/whale_alert/status/1928867003378397425">reported</a> a 104.13 million DOGE transfer, worth around $20 million, to Coinbase on May 31, sparking some concerns over potential sell pressure.
Coinglass data shows Dogecoin liquidations in the past 24 hours at $3.6 million, with $2.39 million in short liquidations. Open interest in a single day spiked 3.2% while DOGE derivatives trading volume expanded by 12.4%. Options volume is up by 185%.
Community News: On June 1, Dogecoin Foundation's senior software engineer Ed Tubbs <a href="https://x.com/EdTubbs/status/1929236466166558746">announced</a> the release of libdogecoin v0.1.4, which introduces Trusted Execution Environment (TEE) for secure key management and signatures.
With this upgrade, Dogecoin becomes one of the first cryptocurrencies to support TEE, a feature designed to enhance wallet security in the face of rising threats across the crypto ecosystem.
Currently, DOGE boasts $1.06 billion in trading volume, reflecting growing market interest.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45624852/dogecoins-chart-screams-caution-as-bulls-get-rejected-again">Dogecoin&#8217;s Chart Screams Caution As Bulls Get Rejected Again</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Dogecoin Could Explode For A 2,100% Gain If This Pattern Holds, Trader Warns

Effective June 2, 2025, Ernexa Therapeutics Inc. (the &quot;Company&quot;), filed a certificate of amendment to the Company&#39;s Restated Certificate of Incorporation, as amended (the &quot;Amended COI&quot;) with the Secretary of State of Delaware to increase the authorized shares of its common stock from 100,000,000 to 150,000,000.
&nbsp;
Additionally, effectively June 2, 2025, the Company filed a certificate of amendment to its Amended COI with the Secretary of State of Delaware to allow for action required or permitted to be taken by stockholders of the Company to be effected by written consent of such stockholders in addition to duly called annual or special meetings of such stockholders.

ERNA

Reported June 2, 2025: Ernexa Therapeutics Amends Certificate Of Incorporation To Increase Authorized Common Stock From 100M To 150M Shares

New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI&#xAE;&nbsp;remain progression-free
CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in standard and high-risk subgroups across prior lines of treatment
CHICAGO, June 3, 2025 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33 percent (n=32) of patients in the study (n=97) with relapsed or refractory multiple myeloma (RRMM) treated with CARVYKTI&#xAE; (ciltacabtagene autoleucel; cilta-cel) achieved progression-free survival (PFS) of five years or more with a single infusion and no maintenance or subsequent anti-myeloma therapy.1 These data underscore Johnson &amp; Johnson's dedication to advancing transformative therapies that aim to reshape the treatment landscape for patients with multiple myeloma.
In a subset of 12 patients who underwent serial evaluations at a single site, all were minimal residual disease (MRD) negative and imaging negative throughout five years of post-treatment follow-up. Findings were featured in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7507). The data were also simultaneously published in The Journal of Clinical Oncology.

Johnson & Johnson Says New Long-Term CARTITUDE-1 Data Show One-Third Of Patients Treated With CARVYKTI Remain Progression-Free

Stifel analyst Tore Svanberg maintains Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) with a Buy and raises the price target from $69 to $80.

CRDO

Stifel Maintains Buy on Credo Technology Group, Raises Price Target to $80

Telsey Advisory Group analyst Dana Telsey maintains Designer Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>) with a Market Perform and maintains $5 price target.

Telsey Advisory Group Maintains Market Perform on Designer Brands, Maintains $5 Price Target

More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO&#xAE;&nbsp;for 24 months or longer in the Phase 3 PERSEUS study
Data from Phase 3 CEPHEUS study show 60 percent overall MRD negativity (10−5) and improved PFS with DARZALEX FASPRO&#xAE; in transplant-ineligible newly diagnosed patients
CHICAGO, June 3, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced data from two studies highlighting that a DARZALEX FASPRO&#xAE; (daratumumab and hyaluronidase-fihj)-based quadruplet regimen demonstrated deep and sustained minimal residual disease (MRD) negativity rates, and improved long-term progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), regardless of transplant status.1,2,3 Findings were highlighted as oral presentations of an analysis of sustained MRD in transplant-eligible patients from the Phase 3 PERSEUS study (Abstract #7501) and a subgroup analysis of transplant-ineligible patients in the Phase 3 CEPHEUS study (Abstract #7516) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Johnson & Johnson Announces Data From Two Studies Highlighting That DARZALEX FASPRO-Based Quadruplet Regimen Demonstrated Deep And Sustained MRD Negativity Rates, And Improved Long-Term PFS In NDMM Patients

Rumors

CURI

Watching CuriosityStream; Traders Circulate Zacks Under $10 Newsletter Picks Stock

VUZI

Wyr.ai Partners With Vuzix On Launch Of M400 Smart Glasses-Based AI Quality Assurance Inspection Platform; Terms Not Disclosed

D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) with a Buy and maintains $16 price target.

ESLA

D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target

Phase 1 trial demonstrates encouraging clinical activity of investigational&nbsp;immunotherapy for relapsed or refractory multiple myeloma
Novel investigational dual-antigen-targeting&nbsp;immunotherapy binds to B-cell maturation antigen (BCMA) and GPRC5D on myeloma cells, as well as CD3 on T-cells&nbsp;
CHICAGO, June 3, 2025 /PRNewswire/ -- Johnson &amp; Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma. Among the 36 patients who received the recommended phase 2 dose (RP2D), the overall response rate (ORR) was 86.1 percent. In the 27 patients who were naive to BCMA and GPRC5D directed therapies, the ORR was 100 percent at the RP2D. Findings were featured in an oral presentation at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439656-1&amp;h=1437573614&amp;u=https%3A%2F%2Fmeetings.asco.org%2Fmeetings%2F2025-asco-annual-%2520meeting%2F327%2Fprogram-guide%2Fscheduled-sessions&amp;a=2025+American+Society+of+Clinical+Oncology+(ASCO)+Annual+Meeting">2025 American Society of Clinical Oncology (ASCO) Annual Meeting</a> (Abstract #<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439656-1&amp;h=2239716214&amp;u=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2FABSTRACT489908&amp;a=7505">7505</a>). The study will also be featured as one of the six best abstracts during the Plenary Abstracts Session at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439656-1&amp;h=2405979170&amp;u=https%3A%2F%2Fehaweb.org%2Fcongress%2Feha2025-congress%2F&amp;a=2025+European+Hematology+Association+(EHA)+Congress">2025 European Hematology Association (EHA) Congress</a> (Abstract #<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439656-1&amp;h=3428041764&amp;u=https%3A%2F%2Flibrary.ehaweb.org%2Feha%2F2025%2Feha2025-congress%2F4159177%2Frakesh.popat.first-in-human.study.of.jnj-79635322.28jnj-532229.a.novel.html%3Ff%3Dmenu%253D6%252Abrowseby%253D8%252Asortby%253D2%252Amedia%253D3%252Ace_id%253D2882%252Amarker%253D5848%252Afeatured%253D19595&amp;a=S100">S100</a>).

Johnson & Johnson Announces Initial Phase 1 Results Of JNJ-79635322, Investigational TsAb In Patients With Relapsed Or Refractory Multiple Myeloma

WIIM

ENTA

Enanta Pharmaceuticals shares are trading higher after JMP Securities maintained an Outperform rating on the stock and raised its price target from $23 to $24.

A 22-year-old college student called into &#8220;<a href="https://www.youtube.com/watch?v=3Sg4BQWIYyo">The Ramsey Show</a>&#8221; and said he was being financially &#8220;abused&#8221; by his parents. The student, identified only as Tyler, said he had been following Dave Ramsey&#8216;s <a href="http://www.benzinga.com/personal-finance/25/05/45680116/couple-making-200k-wants-to-invest-60-of-their-income-dave-ramsey-says-thats-great-but-build-up-a-fat-juicy-down-payment-for-a-house-instead">baby steps</a> and recently used a school refund to pay off debt. His parents were not happy about it.
<h2 class="wp-block-heading">Student Loan Refund Sparks Family Drama</h2>
&#8220;I got my refund from school in May and it was close to about $4,000—exactly $3,999,&#8221; Tyler told hosts Jade Warshaw and Ken Coleman. &#8220;I used that money to pay off my debt, my car payment, and a little bit of my credit card payment.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
Tyler said his parents were furious, claiming the money was theirs. &#8220;They were just absolutely furious about me, saying that that was their money and about the hard work they did to put me out here,&#8221; he explained.
He summed up the situation in one sentence: &#8220;My parents are financially abusing me.&#8221;
Coleman asked for clarification: was the refund from money Tyler had earned through work, or was it part of a student loan? Tyler said it was a mix of both—federal work-study and student loan overage.
When asked whose name was on the loan, Tyler replied, &#8220;I believe it&#8217;s mom and then me. I believe I&#8217;m the co-signer on it.&#8221;
That raised a red flag for the hosts. &#8220;You should have communicated with the parents because they&#8217;re involved in this financially,&#8221; Coleman told him..
Warshaw agreed, saying that while <a href="https://www.benzinga.com/money/how-to-pay-off-debt">paying off debt</a> was a smart instinct, Tyler should have talked to his mom first. &#8220;If your mom was like, &#8216;Wait a minute, you took this loan money that we&#8217;re both on the hook for to do this thing without consulting both of us,&#8217; I can see that,&#8221; she said.
Trending: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
<h2 class="wp-block-heading">Is It Really Abuse?</h2>
Tyler accused his parents of financially abusing him, but both hosts pushed back on the use of that word.
&#8220;I see no evidence of that,&#8221; Warshaw said bluntly. &#8220;You&#8217;re 22 now. Your parents can make suggestions, they can even try to strong-arm you to do things their way, but you don&#8217;t have to.&#8221;
Coleman was more direct: &#8220;You need to stop saying they&#8217;re financially abusing you because this is not anywhere close to it. It&#8217;s dramatic, and by the way, words matter.&#8221;
Tyler claimed the tension comes from his parents&#8217; spending habits. &#8220;They&#8217;re both spenders&#8230; My mom just bought a brand new Mercedes. My dad spends money constantly on his new truck,&#8221; he said. &#8220;They&#8217;ve always been haggling me for money.&#8221;
He also said they pressured him to help pay for a down payment on a truck—something he didn't want to do. Warshaw responded, &#8220;Then you don&#8217;t have to do it.&#8221;
See Also: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
<h2 class="wp-block-heading">Future Debt Could Tie Him To Parents Even More</h2>
The conversation shifted toward Tyler&#8217;s financial future. He currently has $40,000 in student loans and expects it to reach around $80,000 after finishing his degree in sports management at the University of Tennessee.
&#8220;You&#8217;re following in [your parents&#8217;] footsteps right now because you are taking on debt and you&#8217;re <a href="https://www.benzinga.com/personal-finance/24/11/41914082/dave-ramsey-says-its-stupid-to-go-into-debt-for-a-career-you-dont-borrow-money-to-cross-state-lines">going to an out-of-state school</a>,&#8221; Warshaw said. She advised Tyler to consider in-state options or work his way through school without borrowing more money, especially since his mother is on the loans.
&#8220;Mama&#8217;s going to be breathing down your neck every month, talking about, &#8216;Where&#8217;s the payment? You&#8217;re messing up my credit,'&#8221; she warned. &#8220;And that is going to jack you and her.&#8221;
Coleman added, &#8220;Nobody cares where you get your degree from. There&#8217;s a better way, Tyler.&#8221;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
Image: Shutterstock

'My Parents Are Financially Abusing Me'—A College Kid Used His $3,999 School Refund To Pay Off Debt, But His Parents Say It Belongs To Them

Michael Saylor's Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), the world's largest corporate holder of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) on Monday introduced a new preferred stock product: Series A Stride Preferred (STRD) is designed to provide a <a href="https://www.benzinga.com/crypto/25/06/45718471/michael-saylors-strategy-outperforms-apple-tesla-amazon-and-other-mag-7-stocks-and-its-not-even-close-has-the-bitcoin-treasury-bet-paid-off">high-yield return for long-term investors.</a>
The STRD <a href="https://x.com/saylor/status/1929871463521136697">offering</a> marks the company's third preferred instrument as it continues building a structured and diversified capital stack anchored in Bitcoin exposure.
STRD delivers a fixed 10% dividend with perpetual duration and ranks below Strategy's senior preferred instrument (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRF#NASDAQ">STRF</a>), but above the firm's common equity.
It is structured to sit at the riskier end of the firm's yield curve but compensates investors with its highest payout to date among Strategy's preferred options.
Unlike (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRF#NASDAQ">STRF</a>), which prioritizes capital preservation and mimics the risk profile of investment-grade fixed income, STRD is intended for investors seeking higher returns despite increased subordination.
Meanwhile, Strategy's other product STRK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRK#NASDAQ">STRK</a>) offers an 8% dividend and the added benefit of convertibility, placing it squarely between STRF and STRD in terms of both yield and risk.
Strategy's common stock MSTR remains the base layer of its capital stack, functioning as the firm's core vehicle for leveraged Bitcoin exposure.
The STRD issuance is non-callable in typical market conditions, though it may be repurchased if certain events occur, such as a major corporate restructuring or tax-related change. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45744569/michael-saylors-strategy-to-outperform-bitcoin-heres-how-it-could-happen">Michael Saylor&#8217;s Strategy To Outperform Bitcoin? Here&#8217;s How It Could Happen</a>
Dividends will be distributed quarterly, in cash, but only at the discretion of the board.
The firm claims STRD compares favorably to other high-yield investment vehicles on the market. 
For example, unlike ETFs such as iShares Preferred &amp; Income Securities ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFF#NASDAQ">PFF</a>) and iShares Broad USD High Yield Corporate Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USHY#NASDAQ">USHY</a>), STRD carries no management fees and offers a stronger yield proposition: 10% versus 7–8% for its ETF counterparts, while maintaining comparable volatility.
This new product aligns with Strategy's broader push to merge structured financial instruments with crypto exposure. 
The goal: deliver yield, diversification and exposure to digital assets in formats that fit traditional investment portfolios.
According to the company, the launch of STRD further extends its commitment to modernizing capital formation strategies using a layered and yield-tiered approach rooted in both crypto conviction and financial discipline.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45741645/ethereum-books-record-institutional-inflows-xrp-sees-outflows-what-is-going-on">Ethereum Books Record Institutional Inflows, XRP Sees Outflows: What Is Going On?</a></li>
</ul>
Image: Shutterstock

$BTC

MSTR

iShares S&P US Preferred Stock Index Fund

STRF

STRK

USHY

Strategy Launches STRD Preferred Stock Offering 10% Yield

<ul>
<li>Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI&#xAE; with one-third of patients with relapsed/refractory multiple myeloma progression-free for ≥5 years</li>
<li>CARTITUDE-4 subgroup analyses featured in a poster presentation highlight consistent, durable progression-free and overall survival benefit vs. standard therapies across cytogenetic risk groups as early as second-line therapy</li>
<li>Promising early results from ongoing Phase 1 dose-escalation studies of LB1908 in gastroesophageal cancers and LB2102 in lung cancers underscore potential of next-generation cell therapies &nbsp;</li>
</ul>
SOMERSET, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) (Legend Biotech), a global leader in cell therapy, announced today new long-term results from the CARTITUDE-1 study in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. RRMM patients were treated with a single infusion of CARVYKTI&#xAE; (ciltacabtagene autoleucel; cilta-cel) with no maintenance or subsequent myeloma therapy. Notably, an unprecedented 33% (32 of 97) of patients remained progression-free for five years or more.
These data were featured in an oral presentation at the 2025&nbsp;American Society of Clinical Oncology&nbsp;(ASCO) Annual Meeting (<a href="https://www.globenewswire.com/Tracker?data=SUvaU_r4L_ZQGCtcGNJFmwrN7awYRxvTJx-N64piM7dYeIDzCpoh6j_mHdFQX52t67C83Czvmcia9-49Nw4jEJkkqeoBXxtLV3aq3F2REjHx5e2-DGfM4zrlCFa_8zyYtNWxf7rSBbYfxybbPj60vg==">Abstract #7505</a>). To date, more than 6,500 patients have been treated with CARVYKTI&#xAE;, the first and only CAR T-cell treatment in multiple myeloma to show overall survival benefit vs. standard of care.
In a subset of 12 patients from a single center from this analysis who underwent serial minimal residual disease (MRD) assessments, all 12 patients remained progression-free ≥5 years, were MRD-negative and showed no disease on annual PET/CT scans for five years.

LEGN

Legend Biotech Announces New Long-Term Results From CARTITUDE-1 Study In Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

Press Releases

TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year

Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer

Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors

Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting

Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test

In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions

SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer

National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening

FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Fresenius Medical Care

Hims & Hers Health, Inc. Class A Common Stock

Hims & Hers Health

Hinge Health

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Gr

Labcorp Hldgs

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

Nutex Health

Option Care Health

OPKO Health

Premier

Pennant Gr

Privia Health Gr

RadNet

GeneDx Holdings Corp. - Class A Common Stock

GeneDx Holdings

Piper Sandler

Scotiabank

Canaccord Genuity

Stifel

Barclays

목요일(1일) 캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 로빈후드 마켓츠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), AMD(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), 그리고 팔란티어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)와 관련된 중요한 거래를 했다.
<h3>로빈후드 거래</h3>
아크 인베스트의 ARK 혁신 ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>) 펀드는 로빈후드 마켓츠 주식 210,714주를 매입했다. 이 거래는 목요일 종가인 46.62달러를 기준으로 약 982만 달러에 해당하며, 로빈후드가 최근 예상치를 상회한 <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45138927/whats-going-on-with-robinhood-shares-thursday">1분기 실적</a>을 발표한 이후에 이루어졌다. 로빈후드 주가는 목요일에 5.07% 하락했다. 로빈후드의 암호화폐 거래로 인한 매출이 <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45138927/whats-going-on-with-robinhood-shares-thursday">30% 감소</a>했으며, 이에 따라 블라드 테네프 CEO는 거래량 의존도를 줄이기 위한 다각화 전략을 모색하고 있다.
<h3>AMD 거래</h3>
아크 인베스트는 ARKK 펀드를 통해 26,146주의 AMD 주식을 매입하고, 추가로 ARK 차세대 인터넷 ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#BATS">ARKW</a>) 펀드를 통해 3,082주를 매입했다. 이 거래의 총 가치는 AMD의 종가인 96.65달러를 기준으로 약 280만 달러에 해당한다. AMD 주가는 <a href="https://www.benzinga.com/news/25/04/44876468/whats-going-on-with-amd-stock-14">미국 정부의 AI 칩 수출에 대한 새로운 제한</a>으로 인해 압박을 받고 있으며, 이는 상당한 재고 비용과 예상되는 매출 영향을 초래했다.
<h3>팔란티어 거래</h3>
아크 인베스트는 ARKK 펀드를 통해 팔란티어 테크놀로지스 주식 19,406주를 매도했으며, 이는 종가인 116.20달러를 기준으로 약 225만 달러에 해당한다. 이 결정은 팔란티어의 <a href="https://www.benzinga.com/25/04/45124622/cathie-wood-sells-palantir-shares-worth-2-65-million-ahead-of-earnings-doubles-down-on-this-chip-giant">예정된 실적 발표</a>를 앞두고 이루어졌다. 특히, 우드는 수요일에 팔란티어 주식 265만 달러어치를 매도했다.
<h3>기타 주요 거래</h3>
<ul>
<li>가단트 헬스(GH) 주식 186,812주를 ARKK 펀드를 통해 매입했다.</li>
<li>로블록스(RBLX) 주식 49,969주를 ARKK 펀드에서 매도했다.</li>
<li>10X 지노믹스(TXG) 주식 115,500주를 ARKK 펀드를 통해 매입했다.</li>
<li>오로라 이노베이션(AUR) 주식 184,742주를 ARKQ 펀드를 통해 매입했다.</li>
</ul>
사진 제공: viewimage on Shutterstock.com
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal">Shivdeep Dhaliwal</a>이 편집했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)는 <a href="https://www.benzinga.com/quote/PFE/earnings" target="_blank" rel="noopener">4월 29일 화요일</a> 개장 전에 1분기 실적을 발표할 예정이다.
애널리스트들은 뉴욕에 본사를 둔 화이자가 주당 68센트의 분기 수익을 발표할 것으로 예상하고 있다. 이는 전년 동기 82센트에 비해 감소한 수치다. 또한 140억 9천만 달러의 분기 매출을 발표할 것으로 예상되며, 이는 전년 동기 148억 8천만 달러에 비해 감소한 수치다.
가단트 헬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>)는 4월 24일 화이자와의 전략적 협력 관계를 발표하여 화이자의 종양학 포트폴리오 개발 및 상용화를 지원할 예정이다. 이러한 협력은 가단트 인피니티(Guardant Infinity) 스마트 액체 생검 플랫폼을 활용할 것이다.
화이자 주가는 월요일 0.6% 상승하여 23.05달러로 마감했다.
Benzinga 독자들은 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie" target="_blank" rel="noopener">애널리스트 주식 평가</a> 페이지에서 최신 애널리스트 평가를 확인할 수 있다. Benzinga의 가장 정확한 애널리스트들이 <a href="https://www.benzinga.com/quote/pfe/analyst-ratings" target="_blank" rel="noopener">최근에 화이자를 어떻게 평가했는지</a> 살펴보자.
<ul>
<li>UBS 애널리스트 트렁 후인(Trung Huynh): 2025년 4월 8일, 중립 등급을 유지하고 목표주가를 28달러에서 24달러로 하향 조정, 정확도는 66%</li>
<li>골드만삭스 애널리스트 아사드 하이더(Asad Haider): 2025년 4월 8일, &#8216;매수&#8217;에서 &#8216;중립&#8217;으로 하향 조정하고 목표주가를 32달러에서 25달러로 하향 조정, 정확도는 63%</li>
<li>구겐하임 애널리스트 바밀 다이반(Vamil Divan): 2025년 3월 18일, &#8216;매수&#8217; 등급을 재확인, 정확도는 75%</li>
<li>씨티그룹 애널리스트 앤드류 바움(Andrew Baum): 2025년 1월 28일, 중립 등급을 유지하고 목표주가를 30달러에서 29달러로 하향 조정, 정확도는 70%</li>
<li>모건스탠리 애널리스트 테렌스 플린(Terence Flynn): 2024년 10월 30일, 동일비중 등급을 유지하고 목표주가를 30달러에서 31달러로 상향 조정, 정확도는 66%</li>
</ul>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" class="alignnone size-medium" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29024412/image-202-1024x592.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=2048" width="1024" height="592" /></figure>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 8개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 오클로(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>)의 주식은 금요일 회사가 R파워와 <a href="https://www.benzinga.com//node/43061545" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">데이터 센터를 위한 청정 에너지 제공</a>에 대한 MoU를 체결했다고 발표한 후 72.60% 상승했다.
2. 템퍼스 AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>)의 주식은 전 하원의장 낸시 펠로시가 해당 기술 회사에 대한 새로운 <a href="https://www.benzinga.com//node/43097979" target="_blank" rel="noreferrer noopener">지분을 공개한</a> 후 47.91% 급등했다.
3. 하이맥스 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIMX#NASDAQ">HIMX</a>)의 주식은 49.52% 상승했다.
4. 슈퍼 그룹 (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>)의 주식은 회사가 4분기 및 2024 회계연도 매출이 <a href="https://www.benzinga.com//node/43124235" target="_blank" rel="noreferrer noopener">애널리스트 예상치를 초과할 것이라고 발표한</a> 후 38.11% 급등했다. 또한, 캐너코드 제뉴이티(Canaccord Genuity)의 애널리스트 그레이엄 마이클(Michael Graham)이 주식을 보유에서 매수로 상향 조정하고 <a href="https://www.benzinga.com/quote/sghc/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가를 $5에서 $10으로 상향 조정</a>했다.
5. 누스케일 파워(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>)의 주식은 산티 쿠퍼(Santee Cooper)가 사우스 캐롤라이나에서 원자로 건설을 재개할 구매자를 찾고 있다는 최근 보도로 인해 37.92% 상승했다.
6. WNS (홀딩스) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>)의 주식은 3분기 <a href="https://www.benzinga.com//node/43154487" target="_blank" rel="noreferrer noopener">실적이 예상보다 좋고 강력한 가이던스를 발표한</a> 후 36.30% 상승했다. 애널리스트들이 주식의 목표 주가를 <a href="https://www.benzinga.com/quote/wns/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정</a>했다.
7. 가든트 헬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>)의 주식은 회사가 회사가 <a href="https://www.benzinga.com//node/43110223" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">대장암 환자의 검사 테스트</a>를 위한 가든트 리빌(Guardant Reveal)에 대한 메디케어 보장을 발표한 후 주가는 26.53% 상승했다.
8. 리제티 컴퓨팅(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>)의 주식은 기술과 AI 주식의 강세로 인해 25.48% 상승했다. 투자자들이 새로운 <a href="https://www.benzinga.com//node/43119243" target="_blank" rel="noreferrer noopener">정부의 정책과 AI 노력</a>을 평가하고 있다.
이미지 출처: Shutterstock
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%84%B7%ED%94%8C%EB%A6%AD%EC%8A%A4-%ED%8C%94%EB%9E%80%ED%8B%B0%EC%96%B4-%EB%AA%A8%EB%8D%94%EB%82%98-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC/" target="_blank" rel="noopener">넷플릭스, 팔란티어, 모더나는 지난 주 상위 12개 대형주 상승 종목 중 하나입니다 (1월 20일-1월 24일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%9D%BC%EB%A0%89%ED%8A%B8%EB%A1%9C%EB%8B%89-%EC%95%84%EC%B8%A0-%EB%A6%AC%EB%B9%84%EC%95%88-%EB%B0%8F-%EC%9B%94%EA%B7%B8%EB%A6%B0%EC%8A%A4-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%ED%95%98%EB%9D%BD/" target="_blank" rel="noopener">일렉트로닉 아츠, 리비안, 월그린스는 지난 주 상위 13개 대형주 하락 종목 중 하나입니다 (1월 20일-1월 24일)</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 11개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 이나리 메디컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NARI#NASDAQ">NARI</a>)의 주식은 스트라이커(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>)이 주당 80달러 또는 약 49억 달러의 지분 가치를 제시하며 회사를 인수하기로 합의한 후 53.07% 급등했다.
2. 유니퍼스트 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/42878530" target="_blank" rel="noreferrer noopener">1분기 실적을 발표</a>한 후 29.58% 상승했다.
3. 플러그 파워(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>)의 주식은 미국 재무부가 45V 생산세액 공제에 대한 최종 지침을 발표하여 <a href="https://www.benzinga.com/topic/hydrogen" target="_blank" rel="noreferrer noopener">더 친환경적인 수소 미래</a>를 위한 기반을 마련한 후 23.18% 상승했다. 플러그 파워는 이로 인해 혜택을 받을 것으로 예상된다.
4. 페이코 HCM(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>)의 주식은 회사가 페이첵스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>)에 의해 약 41억 달러의 기업 가치를 지닌 현금 거래로 전액 인수될 것이라고 발표한 후 20.77% 상승했다.
5. MP 머티리얼즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>)의 주식은 20.50% 상승했다.
6. 스프링웍스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>)의 주식은 인수 관심 소문 속에서 19.18% 상승했다.
7. 프론트라인 Plc(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>)의 주식은 아마도 도널드 트럼프 당선자가 바이든 대통령의 해양 시추 금지 조치를 철회하겠다고 말한 후 17.29% 상승했을 것이다.
8. 가든트 헬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>)의 주식은 15.53% 상승했다. 회사는 쉴드(Shield) 다중암 검출 테스트가 <a href="https://www.benzinga.com//node/42842047" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">국립암연구소(National Cancer Institute)의 뱅가드 연구(Vanguard Study)</a>에 선정되었다고 밝혔다.
9. GDS 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>)의 주식은 15.40% 상승했다.
10. 카프리 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>)의 주식은 프라다가 카프리 베르사체의 잠재적 구매자가 될 수 있다는 보도가 나오는 가운데 주가는 15.04% 상승했다.
11. 이퀴녹스 골드(AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EQX#AMEX">EQX</a>)의 주식은 14.88% 상승했다. 회사는 4분기에 213,960온스의 금을 생산했으며, <a href="https://www.benzinga.com//node/42888339" target="_blank" rel="noreferrer noopener">2024년에는 621,870온스를 생산</a>했다고 보고했다.
사진 제공: Plug Power
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%9B%94%EA%B7%B8%EB%A6%B0%EC%8A%A4-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%A0-%EB%8D%B8%ED%83%80-%ED%95%AD%EA%B3%B5%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC/" target="_blank" rel="noopener">월그린스, 마이크론, 델타 항공은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (1월 6일-10일)</a></li>
</ul>
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%AA%A8%EB%B9%8C%EC%95%84%EC%9D%B4-%ED%8C%94%EB%9E%80%ED%8B%B0%EC%96%B4-%EB%B0%8F-%EC%96%B4%ED%8E%8C-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4/" target="_blank" rel="noopener">모빌아이, 팔란티어 및 어펌 지난주 최악의 성과를 보인 9개 대형주 중 일부 (1월 6일-10일)</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Guardant Health

뉴스

에 대한 최신 뉴스 Guardant Health (NASDAQ:GH) 주식

금요일, 5월 02, 2025

화요일, 4월 29, 2025

월요일, 1월 27, 2025

일요일, 1월 12, 2025

금요일, 8월 09, 2024

금요일, 7월 19, 2024

목요일, 5월 30, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌